Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Keep me logged in Forgot your password?

Please wait...

Please wait...

CUVPOSA

Compare CUVPOSA  to:
Compare
Compare
CUVPOSA (glycopyrrolate) 1mg/5mL liquid by Shionogi

Generic Name for CUVPOSA

Glycopyrrolate 1mg/5mL; soln; cherry-flavored.

Legal Classification:

Rx

Pharmacological Class for CUVPOSA

Anticholinergic.

Manufacturer of CUVPOSA

Shionogi, Inc.

Indications for CUVPOSA

To reduce chronic severe drooling in patients 3–16yrs of age with neurologic conditions associated with problem drooling (eg, cerebral palsy).

Adult dose for CUVPOSA

Not applicable.

Children's dosing for CUVPOSA

<3yrs: not recommended. Use accurate measuring device. Take on empty stomach. 3–16yrs: initially 0.02mg/kg 3 times daily; may titrate in increments of 0.02mg/kg every 5–7 days based on response and adverse reactions. Max 0.1mg/kg 3 times daily, not to exceed 1.5–3mg per dose based upon weight. See literature.

Contraindications for CUVPOSA

Conditions that preclude anticholinergic therapy (eg, glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon, myasthenia gravis). Concomitant potassium chloride solid oral dosage forms (passage through GI may be arrested or delayed).

Warnings/Precautions for CUVPOSA

Monitor for constipation esp. within 4–5 days of initial dosing or after dose increase. Discontinue if incomplete mechanical intestinal obstruction develops (diarrhea may be early symptom). Autonomic neuropathy. Renal impairment. Ulcerative colitis (esp. large doses). Hyperthyroidism. Cardiovascular disease. CHF. Arrhythmias. Tachycardia. Hypertension. Hiatal hernia associated with reflux esophagitis. Avoid high environmental temperature. Pregnancy (Cat.C). Nursing mothers.

Interactions for CUVPOSA

See Contraindications. May potentiate digoxin slow dissolution oral tabs; monitor and consider using other forms (eg, elixir, caps). Additive antichlolinergic effects with amantadine; consider reducing glycopyrrolate dose. May potentiate atenolol, metformin; consider dose reduction. May antagonize haloperidol (closely monitor or avoid), levodopa (consider increasing dose).

Adverse Reactions for CUVPOSA

Dry mouth, vomiting, constipation, flushing, nasal congestion; drowsiness, blurred vision, intestinal pseudo-obstruction, mechanical intestinal obstruction.

How is CUVPOSA supplied?

Soln—16oz

Related Disease:

Drooling

Related Resources

IMFAR: Genetic Variants Predict Autism Risk in Siblings

May 18, 2012

For siblings of children with autism, a gender-specific genetic score based on single nucleotide polymorphisms (SNPs) in genes with biological and functional relevance to autism can predict the risk of developing an autism spectrum disorder (ASD).

Leukoencephalopathy Risk Factors ID'd for MS Drug

May 17, 2012

Multiple sclerosis patients taking natalizumab are at higher risk of developing progressive multifocal leukoencephalopathy (PML) if they are positive for the anti-JC virus antibodies, have been treated with immunosuppressants, and have been treated with natalizumab for longer periods.

SNCA Variants Linked to Motor Function Decline in Parkinson's

May 17, 2012

Variants of the alpha-synuclein gene (SNCA) are associated with a higher risk of a more rapid decline in motor function in patients with Parkinson's disease.

Many People With Dementia Die at Home

May 16, 2012

Individuals with dementia often live and die at home, and most transitions to a nursing home follow hospitalization.

US Lifetime Prevalence of Sleep Walking ~30 Percent

May 15, 2012

The lifetime prevalence of nocturnal wandering with abnormal state of consciousness (NW) is approximately 30% in the US general population.

Dextroamphetamine sulfate tablets

Central Nervous System > ADHD/narcolepsy

Dextroamphetamine sulfate 5mg, 10mg; scored tabs.

EDLUAR

Central Nervous System > Insomnia

Zolpidem tartrate 5mg, 10mg; sublingual tabs.

EXELON PATCH

Central Nervous System > Alzheimer's dementia

Rivastigmine 4.6mg/24hours, 9.5mg/24hours; transdermal system.

INVEGA SUSTENNA

Central Nervous System > Psychosis

Paliperidone (as palmitate) 39mg, 78mg, 117mg, 156mg, 234mg; ext-rel susp for IM inj.

Updated: 10/7/2009

PROVIGIL

Central Nervous System > ADHD/narcolepsy

Modafinil 100mg, 200mg+; tabs; +scored.

KEPPRA

Central Nervous System > Seizure disorders

Updated Indications: include patients ≥1 month old. Updated Children's dose.

Updated: 4/27/2012

 

KEPPRA ORAL SOLUTION

Central Nervous System > Seizure disorders

Updated Indications: include patients ≥1 month old. Updated Children's dose.

Updated: 4/27/2012

 

LATUDA

Central Nervous System > Psychosis

Adverse reactions updated. How supplied updated.

Updated: 5/11/2012

 

TYSABRI

Central Nervous System > Multiple sclerosis

Updated Warnings/Precautions: Monitor for PML.

Updated: 5/1/2012

 

VYVANSE

Central Nervous System > ADHD/narcolepsy

Adults: OK'd for maintenance treatment in adults 18–55yrs old.

Updated: 5/3/2012

 

Central Nervous System > ADHD/narcolepsy

Narcolepsy, Shift work sleep disorder, Obstructive sleep apnea/hypopnea syndrome ANTINARCOLEPTIC (eg, sodium oxybate): While its mechanism of action is ...
more »

Central Nervous System > Alzheimer's dementia

None of the available treatments for Alzheimer's dementia are curative or are known to reverse or halt the process of ...
more »

Central Nervous System > Anxiety/OCD

BENZODIAZEPINES (eg, alprazolam, lorazepam): Benzodiazepines are believed to exert their anxiolytic effects through enhancement of the GABA-benzodiazepine receptor complex. Gamma-aminobutyric ...
more »

Central Nervous System > Insomnia

Insomnia may be a comorbid condition to many diseases including cancer, HIV, arthritic conditions, heart disease, diabetes, and obesity. It ...
more »

Central Nervous System > Mood disorders

ATYPICAL ANTIPSYCHOTICS (eg, quetiapine, risperidone): The effect of atypical antipsychotics as mood stabilizers for the treatment of bipolar disorder can ...
more »

Mood Disorder Treatments

May 16, 2012

Mood disorder treatments for bipolar disorder, major depressive disorder, treatment resistant depression, premenstrual dysphoric disorder, and others.

Dosing and Titration of Commonly Used Antipsychotics

May 16, 2012

Antipsychotic dosing and titration chart of commonly used first-generation and second-generation antipsychotics.

Daily Dose Thresholds for Sedative-Hypnotics

April 16, 2012

Sedative-hypnotic medications daily dose threshold chart, especially for long term care patients.

ADHD Medications

March 09, 2012

Attention Deficit Hyperactivity Disorder (ADHD) treatment chart.

Daily Dose Thresholds for Antipsychotics

February 09, 2012

Antipsychotic daily dose threshold chart.

ClinicalJobAdvisor

Loading...

More Jobs

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions